Vir Biotechnology (VIR)
Vir Biotechnology on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
16.2M
Short interest
settlement 2026-10-15
6.9
Days to cover
-0.1 days vs prior
54.3%
Short share of volume
2026-10-28
36
Fails to deliver
settlement 2026-08-31
Wed 4 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-28.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in VIR is 16,236,717 shares, down 3,423,954 shares over the last month. Over the last 48 readings it ranged from 5,512,667 shares (15 November 2024) to 21,341,508 shares (31 August 2026). At the reported average volume of 2.3M shares a day that is 6.9 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/vir" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 16,236,717 | +8.4% | 2,347,735 | 6.92 |
| 2026-09-30 | 14,980,532 | -23.8% | 2,138,348 | 7.01 |
| 2026-09-15 | 19,660,671 | -7.9% | 2,075,573 | 9.47 |
| 2026-08-31 | 21,341,508 | +8.9% | 1,921,958 | 11.10 |
| 2026-08-14 | 19,595,909 | +2.9% | 1,438,318 | 13.62 |
| 2026-07-31 | 19,040,209 | +3.2% | 1,556,119 | 12.24 |
| 2026-07-15 | 18,452,974 | -3.9% | 1,541,749 | 11.97 |
| 2026-06-30 | 19,192,724 | +6.1% | 3,209,850 | 5.98 |
| 2026-06-15 | 18,082,921 | -1.3% | 1,515,506 | 11.93 |
| 2026-05-29 | 18,316,762 | +8.8% | 1,694,464 | 10.81 |
| 2026-05-15 | 16,833,002 | +4.4% | 1,537,245 | 10.95 |
| 2026-04-30 | 16,117,209 | -4.1% | 1,655,187 | 9.74 |
| 2026-04-15 | 16,811,002 | -0.2% | 1,913,227 | 8.79 |
| 2026-03-31 | 16,841,179 | +9.1% | 2,189,726 | 7.69 |
| 2026-03-13 | 15,439,503 | +12.9% | 4,205,902 | 3.67 |
| 2026-02-27 | 13,677,336 | +7.0% | 7,780,284 | 1.76 |
| 2026-02-13 | 12,779,376 | +4.5% | 1,460,546 | 8.75 |
| 2026-01-30 | 12,228,838 | +1.9% | 2,026,916 | 6.03 |
| 2026-01-15 | 11,995,546 | +2.1% | 1,888,247 | 6.35 |
| 2025-12-31 | 11,747,085 | +5.4% | 1,834,443 | 6.40 |
| 2025-12-15 | 11,149,646 | +0.3% | 1,969,263 | 5.66 |
| 2025-11-28 | 11,110,359 | +1.1% | 1,596,727 | 6.96 |
| 2025-11-14 | 10,992,709 | +14.7% | 1,375,156 | 7.99 |
| 2025-10-31 | 9,581,029 | -12.4% | 1,541,962 | 6.21 |
| 2025-10-15 | 10,940,671 | -0.1% | 1,419,550 | 7.71 |
| 2025-09-30 | 10,948,379 | -7.6% | 1,187,216 | 9.22 |
| 2025-09-15 | 11,852,892 | -0.6% | 1,235,525 | 9.59 |
| 2025-08-29 | 11,924,295 | +3.8% | 1,848,201 | 6.45 |
| 2025-08-15 | 11,487,884 | +3.1% | 1,172,344 | 9.80 |
| 2025-07-31 | 11,139,128 | -1.4% | 978,884 | 11.38 |
| 2025-07-15 | 11,294,318 | +0.7% | 1,266,004 | 8.92 |
| 2025-06-30 | 11,221,883 | -1.3% | 1,167,336 | 9.61 |
| 2025-06-13 | 11,367,540 | -1.3% | 1,150,229 | 9.88 |
| 2025-05-30 | 11,520,255 | +5.3% | 1,524,899 | 7.55 |
| 2025-05-15 | 10,942,673 | +6.1% | 1,616,001 | 6.77 |
| 2025-04-30 | 10,311,284 | +1.4% | 911,262 | 11.32 |
| 2025-04-15 | 10,167,231 | +0.5% | 1,394,690 | 7.29 |
| 2025-03-31 | 10,114,413 | +28.4% | 1,351,483 | 7.48 |
| 2025-03-14 | 7,880,284 | +1.5% | 1,234,010 | 6.39 |
| 2025-02-28 | 7,765,641 | +1.2% | 1,085,236 | 7.16 |
| 2025-02-14 | 7,670,907 | +0.4% | 1,256,449 | 6.11 |
| 2025-01-31 | 7,637,202 | -2.8% | 1,418,160 | 5.39 |
| 2025-01-15 | 7,855,176 | +19.9% | 6,420,337 | 1.22 |
| 2024-12-31 | 6,553,893 | +7.8% | 1,137,250 | 5.76 |
| 2024-12-13 | 6,080,890 | -1.3% | 1,767,910 | 3.44 |
| 2024-11-29 | 6,163,469 | +11.8% | 1,372,980 | 4.49 |
| 2024-11-15 | 5,512,667 | -3.7% | 1,687,976 | 3.27 |
| 2024-10-31 | 5,721,806 | +3.1% | 893,256 | 6.41 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 28 October 2026, the short share of VIR volume is 54.3%, down 12.8 points over the last five sessions. Over the last 30 readings it ranged from 25.0% (28 September 2026) to 78.0% (22 September 2026). The latest reading is 4.8 points below the 30-session average of 59.1%, on 469K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-28 | 255K | 469K | 54.3% | 4,770 |
| 2026-10-27 | 349K | 656K | 53.2% | 0 |
| 2026-10-26 | 388K | 584K | 66.5% | 0 |
| 2026-10-23 | 416K | 605K | 68.7% | 0 |
| 2026-10-22 | 225K | 376K | 59.9% | 83 |
| 2026-10-21 | 258K | 385K | 67.1% | 0 |
| 2026-10-20 | 349K | 552K | 63.2% | 149 |
| 2026-10-19 | 241K | 438K | 55.0% | 0 |
| 2026-10-16 | 444K | 586K | 75.8% | 309 |
| 2026-10-15 | 336K | 553K | 60.8% | 0 |
| 2026-10-14 | 839K | 1.1M | 77.6% | 0 |
| 2026-10-13 | 242K | 604K | 40.0% | 10 |
| 2026-10-12 | 203K | 335K | 60.6% | 100 |
| 2026-10-09 | 354K | 674K | 52.5% | 4,300 |
| 2026-10-08 | 445K | 817K | 54.4% | 0 |
| 2026-10-07 | 436K | 862K | 50.6% | 1,938 |
| 2026-10-06 | 566K | 925K | 61.2% | 0 |
| 2026-10-05 | 658K | 1.0M | 65.1% | 600 |
| 2026-10-02 | 405K | 624K | 64.8% | 37 |
| 2026-10-01 | 554K | 1.0M | 54.9% | 0 |
| 2026-09-30 | 385K | 565K | 68.3% | 1,014 |
| 2026-09-29 | 275K | 567K | 48.5% | 1 |
| 2026-09-28 | 131K | 523K | 25.0% | 0 |
| 2026-09-25 | 224K | 400K | 56.1% | 0 |
| 2026-09-24 | 435K | 647K | 67.2% | 100 |
| 2026-09-23 | 367K | 598K | 61.3% | 0 |
| 2026-09-22 | 429K | 550K | 78.0% | 600 |
| 2026-09-21 | 214K | 461K | 46.5% | 200 |
| 2026-09-18 | 331K | 544K | 60.9% | 603 |
| 2026-09-17 | 370K | 666K | 55.5% | 257 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 31 August 2026, the fails-to-deliver balance in VIR is 36 shares, down 5,057 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (18 June 2026) to 81,409 shares (20 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-31 | 36 | $10.83 | $390 |
| 2026-08-19 | 5,093 | $9.49 | $48K |
| 2026-08-17 | 72 | $9.24 | $665 |
| 2026-08-11 | 1,445 | $8.89 | $13K |
| 2026-08-06 | 183 | $9.11 | $2K |
| 2026-08-04 | 12,632 | $8.90 | $112K |
| 2026-07-31 | 22 | $8.90 | $196 |
| 2026-07-30 | 22 | $8.64 | $190 |
| 2026-07-24 | 19,975 | $9.34 | $187K |
| 2026-07-22 | 5,900 | $9.42 | $56K |
| 2026-07-20 | 81,409 | $9.43 | $768K |
| 2026-07-16 | 4 | $9.61 | $38 |
| 2026-07-09 | 114 | $10.43 | $1K |
| 2026-07-07 | 715 | $10.02 | $7K |
| 2026-07-02 | 1,593 | $9.56 | $15K |
| 2026-07-01 | 363 | $10.19 | $4K |
| 2026-06-29 | 23,672 | $10.03 | $237K |
| 2026-06-24 | 3,817 | $10.16 | $39K |
| 2026-06-23 | 55,067 | $9.57 | $527K |
| 2026-06-22 | 57,296 | $9.16 | $525K |
| 2026-06-18 | 1 | $9.30 | $9 |
| 2026-06-15 | 370 | $8.61 | $3K |
| 2026-06-08 | 25,698 | $8.65 | $222K |
| 2026-06-03 | 4,952 | $8.74 | $43K |
| 2026-06-02 | 4,520 | $9.03 | $41K |
| 2026-05-22 | 142 | $9.03 | $1K |
| 2026-05-12 | 1,326 | $9.29 | $12K |
| 2026-04-22 | 73 | $10.83 | $791 |
| 2026-04-20 | 1,000 | $10.75 | $11K |
| 2026-04-16 | 632 | $10.46 | $7K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for VIR in the last 90 days. The most recent filings are listed below. Latest filing: Topalian Suzanne Louise (Director) on 2026-10-27.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-27 | Topalian Suzanne Louise | Director | Grant | 5K | $0.00 | $0 | 13K |
| 2026-10-27 | Topalian Suzanne Louise | Director | Grant | 8K | $0.00 | $0 | 8K |
| 2026-08-11 | MORE ROBERT J | Director | Other transaction | 8K | $0.00 | $0 | 518K |
| 2026-08-11 | MORE ROBERT J | Director | Other transaction | 8K | $0.00 | $0 | 41K |
| 2026-06-09 | Coughlin Timothy | Director | Grant | 8K | $0.00 | $0 | 16K |
| 2026-06-09 | Coughlin Timothy | Director | Grant | 8K | $0.00 | $0 | 8K |
| 2026-06-01 | Sabatini Brent | SVP, Chief Accounting Officer | Sell | 379 | $9.45 | $4K | 62K |
| 2026-06-01 | Napolitano Janet | Director | Sell | 3K | $9.45 | $30K | 21K |
| 2026-05-27 | Sigal Charles Elliott | Director | Grant | 8K | $0.00 | $0 | 40K |
| 2026-05-27 | Napolitano Janet | Director | Grant | 8K | $0.00 | $0 | 24K |
| 2026-05-27 | MORE ROBERT J | Director | Grant | 8K | $0.00 | $0 | 49K |
| 2026-05-27 | Hatfield Jeffrey S. | Director | Grant | 8K | $0.00 | $0 | 40K |
| 2026-05-27 | Farid Ramy | Director | Grant | 8K | $0.00 | $0 | 32K |
| 2026-05-27 | BISCHOFBERGER NORBERT W | Director | Grant | 8K | $0.00 | $0 | 21K |
| 2026-05-01 | SATO VICKI L | Director | Sell | 22K | $10.05 | $221K | 1.1M |
| 2026-04-29 | De Backer Marianne | President and CEO | Other transaction | 234K | $0.00 | $0 | 287K |
| 2026-04-29 | De Backer Marianne | President and CEO | Other transaction | 234K | $0.00 | $0 | 715K |
| 2026-04-06 | De Backer Marianne | President and CEO | Sell | 73K | $9.16 | $664K | 948K |
| 2026-04-01 | SATO VICKI L | Director | Sell | 22K | $9.07 | $200K | 1.1M |
| 2026-03-23 | Sabatini Brent | SVP, Chief Accounting Officer | Sell | 8K | $9.12 | $70K | 62K |
| 2026-03-20 | O'Byrne Jason | EVP & Chief Financial Officer | Other transaction | 3K | $0.00 | $0 | 3K |
| 2026-03-20 | O'Byrne Jason | EVP & Chief Financial Officer | Other transaction | 3K | $0.00 | $0 | 160K |
| 2026-03-02 | SATO VICKI L | Director | Sell | 200 | $9.98 | $2K | 1.1M |
| 2026-03-02 | SATO VICKI L | Director | Sell | 22K | $9.50 | $207K | 1.1M |
| 2026-02-25 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Sell | 14K | $9.82 | $135K | 113K |
| 2026-02-25 | Eisner Mark | EVP and Chief Medical Officer | Sell | 2K | $9.82 | $19K | 154K |
| 2026-02-24 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Sell | 3K | $9.53 | $30K | 127K |
| 2026-02-24 | Sabatini Brent | SVP, Chief Accounting Officer | Sell | 1K | $9.53 | $14K | 70K |
| 2026-02-24 | SATO VICKI L | Director | Sell | 200 | $10.26 | $2K | 1.1M |
| 2026-02-24 | SATO VICKI L | Director | Sell | 42K | $9.75 | $411K | 1.1M |
| 2026-02-24 | SATO VICKI L | Director | Exercise or conversion | 42K | $1.49 | $63K | 1.2M |
| 2026-02-24 | O'Byrne Jason | EVP & Chief Financial Officer | Sell | 2K | $9.53 | $16K | 163K |
| 2026-02-24 | Eisner Mark | EVP and Chief Medical Officer | Sell | 2K | $9.53 | $15K | 156K |
| 2026-02-24 | De Backer Marianne | Chief Executive Officer | Sell | 15K | $9.53 | $141K | 1.0M |
| 2026-02-23 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Sell | 4K | $7.45 | $33K | 130K |
| 2026-02-23 | Sabatini Brent | SVP, Chief Accounting Officer | Sell | 2K | $7.45 | $14K | 71K |
| 2026-02-23 | O'Byrne Jason | EVP & Chief Financial Officer | Sell | 2K | $7.45 | $16K | 164K |
| 2026-02-23 | Eisner Mark | EVP and Chief Medical Officer | Sell | 2K | $7.45 | $16K | 158K |
| 2026-02-23 | De Backer Marianne | Chief Executive Officer | Sell | 19K | $7.45 | $142K | 1.0M |
| 2026-02-22 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Grant | 55K | $0.00 | $0 | 134K |
| 2026-02-22 | Sabatini Brent | SVP, Chief Accounting Officer | Grant | 25K | $0.00 | $0 | 73K |
| 2026-02-22 | O'Byrne Jason | EVP & Chief Financial Officer | Grant | 55K | $0.00 | $0 | 166K |
| 2026-02-22 | Eisner Mark | EVP and Chief Medical Officer | Grant | 55K | $0.00 | $0 | 160K |
| 2026-02-22 | De Backer Marianne | Chief Executive Officer | Grant | 285K | $0.00 | $0 | 1.1M |
| 2026-02-13 | Sabatini Brent | SVP, Chief Accounting Officer | Sell | 2K | $7.79 | $12K | 48K |
| 2026-02-02 | SATO VICKI L | Director | Sell | 22K | $7.71 | $170K | 1.1M |
| 2026-01-02 | SATO VICKI L | Director | Sell | 22K | $5.93 | $130K | 1.2M |
| 2025-12-01 | SATO VICKI L | Director | Sell | 22K | $6.00 | $132K | 1.2M |
| 2025-12-01 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 192K | $5.98 | $1.1M | 13.7M |
| 2025-11-28 | SOFTBANK VISION FUND (AIV M1) L.P. | TenPercentOwner | Sell | 61K | $6.44 | $396K | 13.9M |
| 2025-11-28 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 61K | $6.44 | $396K | 13.9M |
| 2025-11-26 | SOFTBANK VISION FUND (AIV M1) L.P. | TenPercentOwner | Sell | 128K | $6.39 | $818K | 14.0M |
| 2025-11-26 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 128K | $6.39 | $818K | 14.0M |
| 2025-11-25 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 236K | $6.38 | $1.5M | 14.1M |
| 2025-11-24 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 228K | $6.15 | $1.4M | 14.3M |
| 2025-11-17 | O'Byrne Jason | EVP & Chief Financial Officer | Sell | 7K | $5.56 | $38K | 111K |
| 2025-11-05 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Sell | 2K | $5.16 | $12K | 78K |
| 2025-11-03 | de Verneuil Vanina | EVP and General Counsel | Sell | 1K | $5.86 | $8K | 81K |
| 2025-11-03 | SATO VICKI L | Director | Sell | 22K | $5.64 | $124K | 1.2M |
| 2025-10-29 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 100 | $6.49 | $649 | 14.6M |
| 2025-10-28 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 24K | $6.50 | $159K | 14.6M |
| 2025-10-27 | SB INVESTMENT ADVISERS (UK) LTD | TenPercentOwner | Sell | 66K | $6.05 | $402K | 14.6M |
| 2025-10-27 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 66K | $6.05 | $402K | 14.6M |
| 2025-10-24 | SB INVESTMENT ADVISERS (UK) LTD | TenPercentOwner | Sell | 47K | $5.96 | $278K | 14.7M |
| 2025-10-24 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 47K | $5.96 | $278K | 14.7M |
| 2025-10-23 | SB INVESTMENT ADVISERS (UK) LTD | TenPercentOwner | Sell | 154K | $5.99 | $925K | 14.7M |
| 2025-10-23 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 154K | $5.99 | $925K | 14.7M |
| 2025-10-22 | SB INVESTMENT ADVISERS (UK) LTD | TenPercentOwner | Sell | 144K | $6.15 | $887K | 14.9M |
| 2025-10-22 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 144K | $6.15 | $888K | 14.9M |
| 2025-10-21 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 110K | $6.30 | $691K | 15.0M |
| 2025-10-20 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 221K | $6.20 | $1.4M | 15.1M |
| 2025-10-16 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 13K | $6.10 | $78K | 15.3M |
| 2025-10-15 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 17K | $6.07 | $101K | 15.4M |
| 2025-10-10 | SOFTBANK VISION FUND (AIV M1) L.P. | TenPercentOwner | Sell | 2K | $6.08 | $14K | 15.4M |
| 2025-10-10 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 2K | $6.08 | $14K | 15.4M |
| 2025-10-09 | SOFTBANK VISION FUND (AIV M1) L.P. | TenPercentOwner | Sell | 249K | $6.14 | $1.5M | 15.4M |
| 2025-10-09 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 249K | $6.14 | $1.5M | 15.4M |
| 2025-10-08 | SB INVESTMENT ADVISERS (UK) LTD | TenPercentOwner | Sell | 466K | $6.05 | $2.8M | 15.6M |
| 2025-10-08 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 466K | $6.05 | $2.8M | 15.6M |
| 2025-10-07 | SB INVESTMENT ADVISERS (UK) LTD | TenPercentOwner | Sell | 72K | $5.60 | $404K | 16.1M |
| 2025-10-07 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 72K | $5.60 | $404K | 16.1M |
| 2025-10-06 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 74K | $5.69 | $421K | 16.2M |
| 2025-10-03 | SVF Endurance (Cayman) Ltd | 10% owner | Sell | 450K | $5.56 | $2.5M | 16.2M |
| 2025-10-01 | SATO VICKI L | Director | Sell | 22K | $5.84 | $128K | 1.2M |
| 2025-09-02 | SATO VICKI L | Director | Sell | 22K | $4.99 | $110K | 1.3M |
| 2025-08-01 | SATO VICKI L | Director | Sell | 22K | $4.99 | $110K | 1.3M |
| 2025-07-17 | Eisner Mark | EVP and Chief Medical Officer | Sell | 4K | $5.47 | $20K | 105K |
| 2025-07-15 | Eisner Mark | EVP and Chief Medical Officer | Sell | 7K | $5.47 | $37K | 108K |
| 2025-07-01 | SATO VICKI L | Director | Sell | 22K | $5.10 | $112K | 1.3M |
| 2025-06-09 | MORE ROBERT J | Director | Other transaction | 14K | $0.00 | $0 | 41K |
| 2025-06-09 | MORE ROBERT J | Director | Other transaction | 14K | $0.00 | $0 | 510K |
| 2025-06-06 | BISCHOFBERGER NORBERT W | Director | Other transaction | 11K | $0.00 | $0 | 13K |
| 2025-06-06 | BISCHOFBERGER NORBERT W | Director | Other transaction | 11K | $0.00 | $0 | 11K |
| 2025-06-02 | Napolitano Janet | Director | Sell | 3K | $5.05 | $16K | 16K |
| 2025-05-30 | BISCHOFBERGER NORBERT W | Director | Grant | 8K | $0.00 | $0 | 24K |
| 2025-05-30 | Farid Ramy | Director | Grant | 8K | $0.00 | $0 | 24K |
| 2025-05-30 | Hatfield Jeffrey S. | Director | Grant | 8K | $0.00 | $0 | 32K |
| 2025-05-30 | MORE ROBERT J | Director | Grant | 8K | $0.00 | $0 | 55K |
| 2025-05-30 | Napolitano Janet | Director | Grant | 8K | $0.00 | $0 | 20K |
| 2025-05-30 | Ramasastry Saira | Director | Grant | 8K | $0.00 | $0 | 23K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON36 Form 144 notices on file for VIR worth $40.5M at the prices reported; 5 in the last 90 days worth $1.2M. Latest: O'Byrne Jason filed on 2026-09-17 to sell 19,357 shares ($213K) from 2026-09-17.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-17 | O'Byrne JasonFormer Officer | 19K | $213K | 0.011% | 2026-09-17 | Fidelity Brokerage Services LLC |
| 2026-09-09 | O'Byrne JasonFormer Officer | 28K | $315K | 0.017% | 2026-09-09 | Fidelity Brokerage Services LLC |
| 2026-08-25 | O'Byrne JasonFormer Officer | 23K | $243K | 0.014% | 2026-08-25 | Fidelity Brokerage Services LLC |
| 2026-08-24 | O'Byrne JasonFormer Officer | 14K | $142K | 0.008% | 2026-08-24 | Fidelity Brokerage Services LLC |
| 2026-08-21 | O'Byrne JasonFormer Officer | 25K | $245K | 0.015% | 2026-08-21 | Fidelity Brokerage Services LLC |
| 2026-06-29 | Ramasastry SairaFormer Director | 16K | $165K | 0.009% | 2026-06-29 | Fidelity Brokerage Services LLC |
| 2026-06-01 | Sabatini BrentOfficer | 379 | $4K | 0.000% | 2026-06-01 | Fidelity Brokerage Services LLC |
| 2026-06-01 | Napolitano JanetDirector | 3K | $30K | 0.002% | 2026-06-01 | Fidelity Brokerage Services LLC |
| 2026-04-30 | Eisner MarkFormer Officer | 89K | $916K | 0.064% | 2026-04-30 | Fidelity Brokerage Services LLC |
| 2026-04-06 | De Backer MarianneOfficer, Director | 73K | $664K | 0.052% | 2026-04-06 | Fidelity Brokerage Services LLC |
| 2026-03-23 | Sabatini BrentOfficer | 8K | $70K | 0.006% | 2026-03-23 | Fidelity Brokerage Services LLC |
| 2026-03-02 | VICKI LEE SATODirector | 88K | $800K | 0.063% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-25 | de Verneuil VaninaOfficer | 14K | $135K | 0.010% | 2026-02-25 | Fidelity Brokerage Services LLC |
| 2026-02-25 | SVF Endurance (Cayman) LimitedStockholder | 400K | $3.8M | 0.287% | 2026-02-25 | Citigroup Global Markets Inc. |
| 2026-02-25 | Eisner MarkOfficer | 2K | $19K | 0.001% | 2026-02-25 | Fidelity Brokerage Services LLC |
| 2026-02-24 | de Verneuil VaninaOfficer | 3K | $30K | 0.002% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Sabatini BrentOfficer | 1K | $14K | 0.001% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-24 | VICKI LEE SATODirector | 20K | $151K | 0.015% | 2026-02-24 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-24 | O'Byrne JasonOfficer | 2K | $16K | 0.001% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-24 | Eisner MarkOfficer | 2K | $15K | 0.001% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-24 | De Backer MarianneOfficer, Director | 15K | $141K | 0.011% | 2026-02-24 | Fidelity Brokerage Services LLC |
| 2026-02-23 | de Verneuil VaninaOfficer | 4K | $33K | 0.003% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Sabatini BrentOfficer | 2K | $14K | 0.001% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-23 | O'Byrne JasonOfficer | 2K | $16K | 0.002% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-23 | Eisner MarkOfficer | 2K | $16K | 0.002% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-23 | De Backer MarianneOfficer, Director | 19K | $142K | 0.014% | 2026-02-23 | Fidelity Brokerage Services LLC |
| 2026-02-13 | Sabatini BrentOfficer | 2K | $12K | 0.001% | 2026-02-13 | Fidelity Brokerage Services LLC |
| 2026-01-14 | SVF Endurance (Cayman) LimitedStockholder | 1.3M | $8.5M | 0.899% | 2026-01-14 | BTIG, LLC |
| 2026-01-02 | VICKI LEE SATODirector | 66K | $398K | 0.047% | 2026-01-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-25 | SVF Endurance (Cayman) Limited10% Stockholder | 1.3M | $8.1M | 0.899% | 2025-11-25 | BTIG, LLC |
| 2025-11-17 | O'Byrne JasonOfficer | 7K | $38K | 0.005% | 2025-11-17 | Fidelity Brokerage Services LLC |
| 2025-11-05 | de Verneuil VaninaOfficer | 2K | $12K | 0.002% | 2025-11-05 | Fidelity Brokerage Services LLC |
| 2025-11-03 | de Verneuil VaninaOfficer | 1K | $8K | 0.001% | 2025-11-03 | Fidelity Brokerage Services LLC |
| 2025-10-21 | SVF Endurance (Cayman) Limited10% Stockholder | 834K | $5.2M | 0.601% | 2025-10-21 | BTIG, LLC |
| 2025-10-03 | SVF Endurance (Cayman) Limited10% Stockholder | 1.7M | $9.5M | 1.201% | 2025-10-03 | BTIG, LLC |
| 2025-10-01 | VICKI LEE SATODirector | 66K | $377K | 0.048% | 2025-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON14 holders report 5% or more of VIR in their latest filing, 8 on Schedule 13D (active intent). The largest reported stake is BlackRock, Inc. at 12.4% of the class (20,905,681 shares), filed 2026-10-27 for an event on 2026-09-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-27 | 13G/Ano. 4 | BlackRock, Inc.parent holding company | 20.9M | 12.4% | 2026-09-30 |
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 10.0M | 5.9% | 2026-06-30 |
| 2026-07-31 | 13G/Ano. 1 | Vanguard Portfolio Managementinvestment adviser | 11.6M | 6.8% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 4 | SoftBank Vision Fund (AIV M1) L.P.partnership | 10.9M | 6.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | SB Investment Advisers (UK) Limitedcorporation | 10.9M | 6.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | SVF Endurance (Cayman) Limitedcorporation | 10.9M | 6.5% | 2026-03-31 |
| 2026-03-27 | 13G/Ano. 3 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-03-03 | 13D/Ano. 7 | Robert Nelsenindividual | 13.5M | 8.5% | 2026-02-27 |
| 2026-03-03 | 13D/Ano. 7 | Keith Crandellindividual | 13.2M | 8.3% | 2026-02-27 |
| 2026-03-03 | 13D/Ano. 7 | ARCH Venture Fund IX Overage, L.P.partnership | 12.9M | 8.1% | 2026-02-27 |
| 2026-03-03 | 13D/Ano. 7 | ARCH Venture Fund IX, L.P.partnership | 12.9M | 8.1% | 2026-02-27 |
| 2026-03-03 | 13D/Ano. 7 | ARCH Venture Partners IX, L.P.partnership | 12.9M | 8.1% | 2026-02-27 |
| 2026-03-03 | 13D/Ano. 7 | ARCH Venture Partners IX Overage, L.P.partnership | 12.9M | 8.1% | 2026-02-27 |
| 2026-03-03 | 13D/Ano. 7 | ARCH Venture Partners IX, LLCother entity | 12.9M | 8.1% | 2026-02-27 |
| 2026-03-03 | 13D/Ano. 7 | Clinton Bybeeindividual | 13.0M | 8.1% | 2026-02-27 |
13F holders
Tracked managers holding VIR at their latest 13F. JSON7 of the 30 tracked managers held VIR at their latest 13F, $100.2M in total at quarter-end prices. Point72 Asset Management is the largest at $57.7M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 5.7M | $57.7M | 0.06% | +3.7M |
| Two Sigma Investments | 2026-06-30 | 1.1M | $11.3M | 0.01% | -329K |
| Renaissance Technologies | 2026-06-30 | 1.0M | $10.4M | 0.01% | +256K |
| Citadel Advisors | 2026-06-30 | 991K | $10.1M | 0.00% | -1.1M |
| AQR Capital Management | 2026-06-30 | 581K | $5.9M | 0.00% | +15K |
| D. E. Shaw & Co. | 2026-06-30 | 416K | $4.2M | 0.00% | -401K |
| Millennium Management | 2026-06-30 | 48K | $489K | 0.00% | -441K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Vir Biotechnology reported revenue of $238.9M, up 19582.5% from the same quarter a year earlier, and net income of $80.1M (0.47 diluted EPS). In FY 2025 it generated -$391.8M of operating cash flow.
- Cash
- $278.7M
- Equity
- $982.5M
- Total assets
- $1.21B
- Shares outstanding
- 169,215,958
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $238.9M | $80.1M | 33.5% | 0.47 |
| Q1 FY 2026 | 2026-03-31 | -$29K | -$125.7M | n/a | -0.85 |
| Q4 FY 2025derived | 2025-12-31 | $64.1M | -$42.9M | -67.0% | n/a |
| Q3 FY 2025 | 2025-09-30 | $240K | -$163.1M | -67975.4% | -1.17 |
| Q2 FY 2025 | 2025-06-30 | $1.2M | -$111.0M | -9139.9% | -0.80 |
| Q1 FY 2025 | 2025-03-31 | $3.0M | -$121.0M | -3989.6% | -0.88 |
| Q4 FY 2024derived | 2024-12-31 | $12.4M | -$104.6M | -845.2% | n/a |
| Q3 FY 2024 | 2024-09-30 | $2.4M | -$213.7M | -8979.7% | -1.56 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $68.6M | -$438.0M | -$391.8M | $4.8M | n/a | n/a |
| FY 2024 | 2024-12-31 | $74.2M | -$522.0M | -$446.4M | $7.3M | n/a | n/a |
| FY 2023 | 2023-12-31 | $86.2M | -$615.1M | -$778.8M | $21.6M | n/a | n/a |
| FY 2022 | 2022-12-31 | $1.62B | $515.8M | $1.66B | $68.0M | n/a | n/a |
| FY 2021 | 2021-12-31 | $1.10B | $528.6M | -$47.6M | $21.8M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-29 from the cover page.
What this page is
Vir Biotechnology in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Vir Biotechnology (VIR), SEC CIK 1706431, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-28.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-08-31.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-17.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-27.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-05.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-27.JSON and CSV
- Company record
- EDGAR filing index for CIK 1706431Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
Other company pages
Datasets
Frequently Asked Questions
How much of VIR is sold short?
16,236,717 shares were held short at the 2026-10-15 settlement, 6.9 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is VIR's daily short volume?
On 2026-10-28, 254,843 of the 469,243 VIR shares reported to FINRA were sold short, 54.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does VIR have fails to deliver?
The SEC's latest file shows 36 VIR shares failed to deliver at settlement 2026-08-31. Fails are reported per settlement date and published twice a month with a lag.
Are VIR insiders buying or selling?
No open-market insider trades were reported for VIR in the last 90 days. The most recent filings are listed below. Latest filing: Topalian Suzanne Louise (Director) on 2026-10-27.
Have VIR insiders filed to sell?
36 Form 144 notices on file for VIR worth $40.5M at the prices reported; 5 in the last 90 days worth $1.2M. Latest: O'Byrne Jason filed on 2026-09-17 to sell 19,357 shares ($213K) from 2026-09-17.
Who owns 5% or more of VIR?
14 holders report 5% or more of VIR in their latest filing, 8 on Schedule 13D (active intent). The largest reported stake is BlackRock, Inc. at 12.4% of the class (20,905,681 shares), filed 2026-10-27 for an event on 2026-09-30.
What did VIR report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Vir Biotechnology reported revenue of $238.9M, up 19582.5% from the same quarter a year earlier, and net income of $80.1M (0.47 diluted EPS). In FY 2025 it generated -$391.8M of operating cash flow.
Which tracked 13F managers own VIR?
7 of the 30 tracked 13F managers held VIR shares at their latest filing, $100.2M in all. The largest: Steve Cohen's Point72 Asset Management (5.7M shares, $57.7M), Two Sigma Investments (1.1M shares, $11.3M), Renaissance Technologies (1.0M shares, $10.4M), Ken Griffin's Citadel Advisors (991K shares, $10.1M), Cliff Asness's AQR Capital Management (581K shares, $5.9M), D. E. Shaw & Co. (416K shares, $4.2M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.